Table 3.

Time‐to‐Event Outcomes of the Patients With PE Who Survived the Index Hospitalization Treated by CDT or ST Before and After Propensity Score Weighting

	Data Before IPTW*		Data After IPTW †
Outcome	CDT (n=123)	ST (n=908)	CDT	ST	HR or SHR of CDT (95% CI) ‡	P Value
1‐y Outcome
All‐cause mortality	16 (13.0)	122 (13.4)	12.2	13.2	0.73 (0.56–0.94)	0.015
Recurrent PE	12 (9.8)	160 (17.6)	9.3	17.5	0.52 (0.41–0.66)	<0.001
Heart failure	3 (2.4)	31 (3.4)	3.6	3.4	1.17 (0.68–1.99)	0.576
New‐onset pulmonary hypertension	1 (0.8)	15 (1.7)	0.3	1.6	0.20 (0.06–0.72)	0.013
As of the last follow‐up
All‐cause mortality	34 (27.6)	303 (33.4)	29.5	32.8	0.84 (0.72–0.98)	0.031
Recurrent PE	22 (17.9)	219 (24.1)	22.2	23.9	0.81 (0.68–0.97)	0.021
Heart failure	4 (3.3)	71 (7.8)	4.2	7.6	0.55 (0.37–0.80)	0.002
New‐onset pulmonary hypertension	5 (4.1)	29 (3.2)	1.8	3.1	0.58 (0.33–1.03)	0.065

CDT indicates catheter‐directed thrombolysis; HR, hazard ratio; IPTW, inverse probability of treatment weighting; PE, pulmonary embolism; SHR, subdistribution HR; and ST, systemic thrombolysis.

^*Values are given as number (percentage).

^†Values are given as percentage.

^‡Adjusted for sex, hyperlipidemia, hyperthyroidism, previous stroke, Charlson Comorbidity Index score, statin use, anticoagulant use, and intubation.